MedTrace Logo

Bemiparin Randomized Trial on Bridging Oral Anticoagulants in Invasive Procedures (BERTA Study)

NCT00484822 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2010-02-04

No results posted yet for this study

Summary

Often it is necessary to temporarily discontinue OAT when surgical or other invasive procedures are required. However, there is no consensus on the optimal management in these situations, and heparin bridging therapy is the current usual practice in these situations. No large randomized, controlled clinical trials have been yet performed to evaluate the efficacy and safety of a low molecular weight heparins (LMWH) as bridging therapy.

Conditions

  • Long-term Oral Anticoagulant Therapy

Interventions

DRUG

Bemiparina Sodica

3.500 UI/día.

DRUG

Heparina Cálcica

10.000 UI/día.

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Fontcuberta Boj Jordi, Dr. · Fundació de Gestió Sanitaria del hospital de la Santa Creu i Sant Pau

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Completion
2009-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484822 on ClinicalTrials.gov